We have assessed the release of amethocaine from a new patch delivery system and subsequent drug diffusion through human stratum corneum and whole skin. We found that the patch system was more efficient than an amethocaine gel preparation. 
The most common form of medically induced pain is that caused by the insertion of needles, for example for venepuncture. It has been reported that one of the major fears of young children in hospital concerns procedures involving needles [1, 2] . Therefore, a rapidly acting topical anaesthetic formulation would be of considerable clinical benefit in reducing the fear, anxiety and pain associated with invasive medical procedures.
Although EMLA, a topical percutaneous anaesthetic gel consisting of prilocaine and lignocaine, provides satisfactory skin anaesthesia, the minimum recommended time of application to ensure adequate anaesthesia is 1 h. The preparation is applied as a thick layer under an occlusive dressing and duration of anaesthetic effect is approximately 30 min. A further problem associated with any cream-or gelbased topical preparations is that the amount of drug applied topically, and area of skin surface involved, are ill-defined.
It has been reported that a percutaneous local anaesthetic gel formulation containing amethocaine base provided more rapid and prolonged anaesthesia than EMLA [3] . The anaesthetic efficacy of this formulation derives partially from the solid-to-liquid phase change which occurs when amethocaine base, in an aqueous environment, is exposed to temperatures of about 29 °C and greater [4] . We have now further developed this amethocaine phase-change system [5] to produce a percutaneous local anaesthetic patch, similar in appearance to many existing typical transdermal therapeutic systems, which allows enhanced shelf-life, greater convenience of use and the precise control of the dose of drug administered. The present study reports on the in vitro penetration characteristics of amethocaine from the new patch system and compares its clinical efficacy against EMLA in a double-blind, placebocontrolled volunteer study.
MATERIALS AND METHODS

Chemicals
Amethocaine base U.S.P. was obtained from Orgamol, Switzerland. EMLA was obtained from Astra Pharmaceuticals Ltd, Hertfordshire, U.K. Trypsin type 11: crude was obtained from Sigma Ltd, Poole, Dorset. All other chemicals were of Analar or HPLC quality.
Formulations
The percutaneous local anaesthetic patches (3x3 cm) contained amethocaine 10 mg and were prepared using conventional pharmaceutical methods [6] . The amethocaine gel formulation was prepared as described previously [3] . Controls, without amethocaine, were similarly prepared. EMLA was repacked into plain tubes and a matching placebo cream was prepared also.
Diffusion studies
In vitro penetration of amethocaine through human skin was undertaken using modified Franz diffusion cells (FDC-400, flat flange, 15-mm orifice diameter, Crown Glass Co., Somerville, NJ, U.S.A.), as described previously [7] . All experiments were conducted in triplicate. Flux values were calculated by linear regression from the linear sections of the concentration per unit area vs time plots.
Amethocaine assay
Amethocaine was assayed by ion-pair reverse phase high pressure liquid chromatography using a Spherisorb 5 mm ODS column (25 cm). The mobile phase consisted of acetonitrile: water (8:2) containing 1-hexanesulphonic acid ion pair reagent 0.005 mol litre" 1 (Waters Ltd, Harrow, U.K.). A Gilson 302 pump was used in combination with an 802 manometric module (Anachem Ltd, Luton, U.K.) and a Rheodyne 7125 injector (20-ul loop). Detection was carried out at 310 run using an LKB 2151 variable-wavelength detector (LKB, Bromma, Sweden). Chromatograms were recorded on a Hewlett-Packard 3390A integrator (HewlettPackard, Wokingham, U.K.). Calibration graphs were linear (r > 0.999) in the range 6.5-55 ug ml" 1 . Procaine hydrochloride was used as the internal standard.
Preparation of human whole skin samples
Healthy skin samples, surplus to limb amputation, were obtained from the Belfast City Hospital. Human whole skin samples were prepared by careful removal of the subcutaneous fat. Skin sections were cut of a size suitable for mounting in the diffusion cells. Prepared skin samples were stored frozen at -18 °C until required.
Preparation of human stratum corneum
Human whole skin was incubated in trypsin solution 0.1% w/v in phosphate-buffered saline, pH 7.2, at 37 °C. The stratum corneum was then peeled carefully from the epidermis, rinsed in water and cut into sections of suitable size.
In vitro studies
The Franz diffusion cell apparatus was configured as previously described [7] . Each drug penetration experiment was performed simultaneously in triplicate using whole skin or stratum corneum samples from the same source. The receiving chamber of each cell was filled with phosphate buffered saline (12 ml, pH 7.2) and allowed to equilibrate for 1 h. Skin samples were placed on a filter support and covered with either samples of the patch or a thin layer (1 mm) of gel, using a casting bar technique. They were then covered with an occlusive membrane (Parafilm). The receiving fluid was stirred continuously and synchronously in all three cells. Samples (0.3 ml) were obtained at intervals, amethocaine concentration was measured and the reservoir topped up with 0.3 ml of phosphate buffered saline. Previous studies have indicated that the amount of amethocaine metabolized during the course of the experiments would be negligible [8] .
Volunteer studies
After obtaining Ethics Committee approval, we studied 20 healthy, trained volunteers (12 female), age range 19-32 yr. Each volunteer gave written informed consent. The purpose of the in vivo study was to compare the speed of onset of anaesthesia, effectiveness and duration of action of the patch delivery system with the gel preparation and EMLA. Because of difficulties with double-blinding this part of the study (there are marked physical differences between the patch and the gel formulations), appropriate placebos were also included for each preparation. Therefore, each volunteer was tested with six preparations, three active and three placebos, in a randomized manner. A minimum period of 7 days elapsed between treatments. The formulations were applied to the ventral surface of the forearm, as described previously [3] . Gel 1.0 g, patch and EMLA 1.0 g were left in contact with the skin for both 30-and 60-min periods of application. After removal of the preparations, the treated sites were wiped clean and anaesthesia was assessed by pin-prick as described previously [9, 10] . Full anaesthesia was allotted a score of 1, partial or no anaesthesia was scored as 0 [3] .
RESULTS
The diffusion of amethocaine through human stratum corneum is shown in figure 1 and that through human whole skin from both formulations, under the same conditions, in figure 2. The flux values obtained from these data are presented in 0.001 < P < 0.05 0.001 < P < 0.05 0.001 < P < 0.05 0.001 < P < 0.05 0.001 < P < 0.05 0.001 < P < 0.05 0.001 < P < 0.05 0.001 < P < 0.05 detailed comparisons. Statistical comparisons of drug fluxes through human stratum corneum and human whole skin are shown in tables II and III, respectively. Table IV gives little effect on the flux values of amethocaine through human stratum corneum, for both gel and patch formulations. It was also observed that the type of formulation used had no significant effect (P > 0.05) on the flux values. The flux of amethocaine obtained when the patch was applied continuously was significantly better (0.001 < P < 0.05) than that provided when either the patch or gel was applied for 30 min. Although the type of amethocaine formulation used had no significant effect (P > 0.05) on the drug flux through human whole skin, time of application (table III) did prove significant (0.001 < P < 0.05). The type of barrier membrane used significantly (0.001 < P < 0.05) affected the flux values obtained for both application times (table IV) .
Initially, the patch formulation was tested for percutaneous anaesthetic efficacy against placebo in a double-blind design. Statistical analysis of the results (chi-square) indicated that it was significantly (P < 0.001) better than placebo. All the other formulations used in this study also provided significantly (P < 0.001) better percutaneous local anaesthesia compared with placebo.
The in vivo efficacy of the gel, patch and EMLA, following both 30-and 60-min periods of application is shown in figure 3 . For the 30-min application time, only the speed of onset of the gel and patch formulations were compared (table V), as EMLA provided anaesthesia only in a small number of volunteers ( fig. 3) . The mean time for onset of skin anaesthesia was 35.3 min for the gel formulation and 34.5 min for the patch. For the 60-min application, however, the three different formulations were compared statistically for speed of onset of anaesthesia, against one another. Application of ANOVA to the data indicated that there was a significant difference between the formulations. Therefore, the Scheffe multiple comparison test was used to obtain more detailed comparisons (table V). The results indicated that both the gel and patch were significantly more rapid than EMLA in providing percutaneous local anaesthesia {P < 0.001) after a 60-min application. In contrast, there was no significant difference between the gel and the patch formulations in onset of anaesthesia (table V) . All volunteers were anaesthetized after the 60-min application when either the gel or patch was used, but this was not the case with EMLA ( fig. 3) , for which the mean time of onset of percutaneous local anaesthesia was 65.3 min.
DISCUSSION
The potential benefits of a patch delivery system for topical percutaneous local anaesthesia are increased safety and convenience of use, reduced drug-loading and application of an accurately known amount of drug onto a clearly defined area of skin. However, because of the different formulation characteristics of a patch in comparison with gel, it was necessary, initially, to examine the release behaviour of amethocaine from the patch in respect of in vitro skin penetration characteristics. It can be observed clearly (figs 1, 2) that diffusion of amethocaine occurred from the patch through both human stratum corneum and whole skin. Not surprisingly, the amount of drug penetrating human whole skin was substantially less than that diffusing across human stratum corneum. Although this difference could be attributed to the greater thickness of whole skin, it was likely that increased protein binding was also reducing penetration of drug [8] . It can be seen also that the patch provided similar flux values through both membranes compared with gel (table I) , despite the total amount of amethocaine applied to the skin samples in the form of the patch being about 50 % that of the gel. This apparent anomaly may be explained by considering the diffusion of amethocaine from the formulations. Effectively, amethocaine penetration into the skin, with either patch or gel formulations, occurs from a saturated drug solution at the formulation-skin interface, the diffusion layer [5] . As drug is depleted from this interface, it is constantly replaced by undissolved amethocaine. Therefore, it would require prolonged application of either formulation in order to deplete completely the available amethocaine in the diffusion layer-a phenomenon recognized with other topical formulations [11] . Therefore, as the hydrated patch simulates a very thin layer of gel, it provides a comparatively efficient method of drug delivery to the skin surface. If amethocaine diffusion across human stratum corneum is considered after a 30-min application time, it can be observed that drug continues to appear in the receiving fluid even after the patch is removed, illustrating the reservoir effect of this tissue. The amount of drug diffusion across stratum corneum stopped after about 2 h, giving a final value of 155 ug cm"
2 . An approximate estimate of the amount of amethocaine contained, as a reservoir, within 1 cm 2 of stratum corneum can be obtained by considering the difference in the amount of drug in the receptor after 30 min compared with that observed when a plateau occurred; this gives a value of about 125 ug.
These data would indicate that about 1.4 mg of drug could diffuse from a 3 x 3 cm patch, which initially contained amethocaine 10 mg. Even when the patch was left on continuously for a 7-h period, the amount of amethocaine diffusing through was about 350 ug cm" 2 . This represents diffusion of approximately 3.2 mg of drug from a similar sized patch. However, it is interesting to observe that, in the latter case, the diffusion rate began to plateau after this prolonged period of time. At this point the drug concentration in the diffusion layer at the skin surface was becoming depleted and the rate of absorption was reduced. This phenomenon provides a potential safety feature, in that an application time extending to several hours would be required to exhaust the patch of drug. It must be emphasized that the projected amounts of amethocaine penetrating the skin, as discussed above, represent an extreme case. Only penetration of the stratum corneum is being considered and amethocaine metabolism, both within the skin and systemically, is ignored [12] . It has been shown [13] that, after application of 5 % amethocaine 2 g to a 6-cm 2 area on the dorsum of the hand for a 4-h period in 10 adult volunteers, amethocaine could be detected in only three subjects. The maximum measured plasma concentration was 200 ng ml" 1 . Although amethocaine, in vivo, is metabolized rapidly to p-(butylamino)benzoic acid [8] , this metabolite could only be detected at a maximum concentration of 820 ng ml" 1 in one volunteer [13] .
In vivo studies on the activity of patch compared with placebo clearly indicated that the former provided effective local anaesthesia similar to that of the gel. Both formulations provided satisfactory anaesthesia in all volunteers ( fig. 3) , although it can be seen that some volunteers were already anaesthetized on removal of both patch and gel formulations after the 30-min application period. It has been shown that a minimum application period of approximately 20 min is necessary to provide percutaneous local anaesthesia [14] . All volunteers were found to be anaesthetized within 15 min after removal of the amethocaine formulations ( fig. 3 ). This delayed action effect can be related to the results from in vitro drug penetration studies, in which amethocaine continued to diffuse into the receiving fluid even after the preparation had been removed from the skin samples ( fig. 1 ). Therefore, a reservoir effect is apparent both in vivo and in vitro. This phenomenon has been well documented after the topical application of various steroids, although the reservoir effect with steroids is much more pronounced than that with amethocaine.
It is clear from figure 3 that EMLA does not produce adequate percutaneous local anaesthesia BRITISH JOURNAL OF ANAESTHESIA after a 30-min application. Although a small number of volunteers were anaesthetized, the effect was of short duration ( fig. 3 ). This is in agreement with previous observations [3] . Both lignocaine and prilocaine, the constituent local anaesthetics of EMLA, are less potent than amethocaine and hence would be required in larger concentrations than the latter drug to produce similar levels of local anaesthesia.
When the time of application was increased to 60 min, there was a marked improvement with the anaesthetic effect of EMLA ( fig. 3) . Although the increased time of application had a less dramatic effect on the behaviour of the amethocaine formulations, some differences were noted; for example, all volunteers were found to be anaesthetized on removal of the formulations ( fig. 3) . It would appear also that an increase in application time tended to cause a concomitant increase in the duration of the anaesthetic effect ( fig. 3 ). There is a marked difference in the duration of action between EMLA and both amethocaine formulations. Thus, even with an application time of 30 min, using the latter formulations, the shortest period during which all volunteers were satisfactorily anaesthetized was just over 3 h. However, it can be observed ( fig. 3 ) that some volunteers had an anaesthetic effect extending beyond 6 h. In contrast, a 60-min application of EMLA resulted in all volunteers being anaesthetized for a minimum of 20 min ( fig. 3) , although some individual volunteers had satisfactory anaesthesia of much longer duration. Although penetration enhancers have been used in an attempt to increase the rate of diffusion of amethocaine through skin, and hence reduce the time required for onset of anaesthesia, these are unlikely to have a clinically significant effect [15] . A liposomal percutaneous anaesthetic formulation containing 0.5 % w/w amethocaine has been shown to produce satisfactory topical anaesthesia [16] . However, when an application time of 30 min was used, a further period of 1.5 h was required for onset of anaesthesia in 80% of the volunteers. This prolonged time for onset of effect is, perhaps, not surprising, considering the design of the formulation: amethocaine is trapped within vesicles from which it must escape before penetrating the skin.
In the present study, only one application site was used as it is well established that various sites of the body provide different challenges to percutaneous penetration. For example, drug penetration is easier through the scalp (or the skin behind the ears), whereas it is more difficult through the palms of the hands or soles of the feet. The main sites for application of percutaneous local anaesthetic formulations would be the ventral surface of the forearm or the dorsum of the hand, for venepuncture. Although it has been suggested that the dorsum of the hand provides a greater barrier to local anaesthetics, in terms of onset of anaesthesia, this does not appear to be a problem when amethocaine is used, particularly in children [17] .
